The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors. 177Lu-edotreotide shows potential to extend ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Median PFS among 99 patients with pNET who were randomized 2:1 to receive cabozantinib ... progression…regardless of primary tumor site and grade. Sharon Worcester, MA, is an award-winning ...

FDA approves Exelixis' Cabometyx for advanced neuroendocrine tumors before ... for other forms of advanced NET, depending on tumor grade and different requirements for prior therapy.

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Ascentage Pharma Group International’s AAPG share price has surged by 7.56%, which has investors questioning if this is right time to sell.

This medication is specifically designed to combat cancer by targeting abnormal growth signals in perivascular epithelioid cells, which multiply uncontrollably in advanced PEComa. By blocking a ...

Learn more about whether LeMaitre Vascular, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from ...

In the BRACELET-1 Phase 2 breast cancer trial, pelareorep plus paclitaxel outperformed ... we are proud to bring CABOMETYX to ...